SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:6470.
  • 2
    Anderson HC, McCarty M. Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever. Am J Med 1950;8:445455.
  • 3
    Anzai T, Yoshikawa AT, Takahashi T, et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003;99:4753.
  • 4
    Atar I, Gulmez O, Atar I, et al. The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. Clin Cardiol 2005;28:243246.
  • 5
    Aviles-Santa L, Salinas K, Adams-Huet B, Raskin P. Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus. J Invest Med 2006;54:2031.
  • 6
    Bach F, Grundmann U, Bauer M, et al. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 2002;46:12271235.
  • 7
    Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004;38:110118.
  • 8
    Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003;107:24092415.
  • 9
    Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361368.
  • 10
    Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 2002;90:942946.
  • 11
    Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: Data from the Heart and Soul Study. Circulation 2003;107:245250.
  • 12
    Berezin AE. Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure. Klin Med (Mosk) 2004;82:2932.
  • 13
    Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999;19:23482354.
  • 14
    Biasucci LM, Lombardi M, Piro M, Di Giannuario G, Liuzzo G, Crea F. Irbesartan significantly reduces C-reactive protein concentrations after one month of treatment in unstable angina. Heart 2005;91:670671.
  • 15
    Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GY. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 2001;88:A78, A89–92.
  • 16
    Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 1989;88:88100.
  • 17
    Brasier AR, Recinos, A, Eledrisi, MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:12571266.
  • 18
    Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:15121521.
  • 19
    Carroll MF, Schade DS. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. Circulation 2003;108:2431.
  • 20
    Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513520.
  • 21
    Cha JK, Jeong MH, Lee KM, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002;14:145150.
  • 22
    Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002;48:877883.
  • 23
    Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405409.
  • 24
    Chyrchel M, Dudek D, Bartus S, Legutko J, Heba G, Dubiel JS. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level inpatients with unstable angina. Kardiol Pol 2004;61:213221.
  • 25
    Claus DR, Osmand APL, Gewurz H. Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med 1976;87:120128.
  • 26
    Coban E, Ozdogan M, Yazicioglu G, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic hypertensive patients. Int J Clin Pract 2005;59:415418.
  • 27
    Coban E, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res 2004;30:343349.
  • 28
    Costa A, Casamitjana R, Casals E, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003;20:743745.
  • 29
    Cummings DM, King DE, Mainous AG C-reactive protein, antiinflammatory drugs, and quality of life in diabetes. Ann Pharmacother 2003;37:15931597.
  • 30
    Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255261.
  • 31
    Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/([a-z])rogestin Interventions (PEPI) Study. Circulation 1999;100:717722.
  • 32
    Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893899.
  • 33
    D'Anna R, Baviera G, Corrado F, et al. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet Gynecol Scand 2005;84:474477.
  • 34
    Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:44964501.
  • 35
    De Maat MP, Kluft C, Gram J, Jespersen J. Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. Circulaton 2003;108:E113.
  • 36
    Devaraj S, Jialal I. Alpha-tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 2000;29:790792.
  • 37
    Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for metabolic syndrome and atherothrombosis. Circulation 2003;107:398404.
  • 38
    Di Napoli M, Papa F. Angiotensin-converting enzyme inhibiter use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003;34:29222929.
  • 39
    Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691697.
  • 40
    Doo YC, Kim DM, Oh DJ, Ryu KH, Rhim CY, Lee Y. Effect of beta-blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris. Am J Cardiol 2001;88:422424.
  • 41
    Feldman M, Jialal I, Devaraj S, Cryer B. E ffects of low dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:20362041.
  • 42
    Fischer CP, Hiscock NJ, Penkowa M, et al. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004;558:633645.
  • 43
    Fliser D, Buchnolz K, Haller H EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:11031107.
  • 44
    Ford ES. Body mass index, diabetes and C-reactive protein among U.S. adults. Diabetes Care 1999;22:19711977.
  • 45
    Fredrikson GN, Hedbland B, Nilsson JA, Alm R, Berglund G, Nilsson J. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 2004;53:14361442.
  • 46
    Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of metabolic syndrome: A population-based study. Diabetes Care 2000;23:18351839.
  • 47
    Fumeron C, Nguyen-Khoa T, Saltiel C, et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005;20:18711879.
  • 48
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448454.
  • 49
    Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:10841091.
  • 50
    Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679684.
  • 51
    Hall WL, Vafeiadou K, Hallund J, et al. Soy isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal woman: Interactions with genotype and equol production. Am J Clin Nutr 2005;82:12601268.
  • 52
    Himmelfarb J, Kane J, McMonagle E, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003;64:978991.
  • 53
    Hung MJ, Cherng WJ, Cheng CW, Yang NI. Effect of antispastic agents (calcium antagonists and/([a-z])r isosorbide dinitrate) on high-sensitivity C–reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Am J Cardiol 2005;95:8487.
  • 54
    Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966;123:365378.
  • 55
    Ikonomidas I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793798.
  • 56
    Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003;91:287292.
  • 57
    Ishikawa T, Imamura T, Hatakeyama K, et al. Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation. Am J Cardiol 2004;93:611614.
  • 58
    Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502510.
  • 59
    Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002;112:269274.
  • 60
    Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:19331935.
  • 61
    Joynt KE, Gattis WA, Hasselbald V, et al. Effect of angiotensin-converting enzyme inhibitors, beta–blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004;93:783785.
  • 62
    Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/([a-z])ovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672678.
  • 63
    Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 2003;145:E8.
  • 64
    Kim SB, Kim SH, Chang JW, et al. Effects of cebecoxib on high–sensitivity C-reactive protein in chronic peritoneal dialysis patients. Ren Fail 2004;26:381384.
  • 65
    Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-1992. Circulation 1999;99:237242.
  • 66
    Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905910.
  • 67
    Koulouris S, Symeonides P, Triantafyllou K, et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:13861388.
  • 68
    Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003;90:124131.
  • 69
    Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon Circulation 1999;100:96102.
  • 70
    Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: A review article. Climacteric 2005;8:317326.
  • 71
    Lee J, Lee M, Kim JU, Song KI, Choi YS, Cheong SS. Carvedilol reduces plasma 8-hydroxy-2-deoxygua-nosine in mild to moderate hypertension: A pilot study. Hypertension 2005;45:986990.
  • 72
    Lee P, Prasad K. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by cyclooxygense inhibitors. Int J Angiol 2003;12:1323.
  • 73
    Li C, Sun BK, Lim SW, et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 2005;79:15221529.
  • 74
    Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003;26:472476.
  • 75
    Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285288.
  • 76
    Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163167.
  • 77
    Lu Q, Bjorkhem I, Wretlind B, Diczfcalusy W, Henriksson P, Freyschuss A. Effect of ascorbic acid on microcirculation in patients with type II diabetes: A randomized placebo-controlled cross-over study. Clin Sci 2005;108:507513.
  • 78
    Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:30323037.
  • 79
    Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial — FAT). Cardiovasc Res 2001;52:290298.
  • 80
    McEvoy GK. Salicylates general statement: Nonsteroid anti-inflammatory agent. In: McEroyGK, ed. AHFS Drug Information 95. Bethesda , MD : The American Society of Health System Pharmacists, 1995;12731285.
  • 81
    Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 2006;5:3751.
  • 82
    Mitrovic V, Klein HH, Krekel N, et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 2005;94:336342.
  • 83
    Mold C, Gewurz H, Du Clos TW Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42:2330.
  • 84
    Monakier D, Mates M, Klutstein MW, et al. Rofecoxib, a COX-2 inhibitor lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004;125:16101615.
  • 85
    Moon YS, Kashyap ML. Niacin extended-release/([a-z])ovastatin: combination therapy for lipid disorders. Expert Opin Pharmacother 2002;3:17681774.
  • 86
    Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149161.
  • 87
    Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998;11:15S22S.
  • 88
    Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 1999;30:981985.
  • 89
    Murphy RT, Foley JB, Tome MT, et al. Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. Free Radic Biol Med 2004;36:959965.
  • 90
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:2938.
  • 91
    Orem C, Orem A, Calapoglu M, Baykan M, Uydu HA, Erdol C. Plasma fibronectin level and its relationship with lipids, lipoproteins and C-reactive protein in patients with dyslipidemia during lipid-lowering therapy. Acta Cardiol 2002;57:421425.
  • 92
    Oubina, MP, De Las Heras, N, Cediel E, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003;105:655662.
  • 93
    Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002;105:457461.
  • 94
    Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemo-attractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:25312534.
  • 95
    Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:21652168.
  • 96
    Pelton GH, Price LH, Heninger GR. E. Proc Am Meeting Am Coll Neuropsychopharmacol 1996;3:459467.
  • 97
    Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:14471452.
  • 98
    Post, MS, Van Der Mooren, MJ, Stehouwer CD, et al. Effects of transdermal and oral estrogen replacement therapy on C-reactive protein levels in postmenopausal women: A randomized, placebo-controlled trial. Thromb Haemost 2002;88:605610.
  • 99
    Potempa LA, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. Stimulation of human neutrophils, monocytes and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 1988;12:391405.
  • 100
    Prasad A, Koh KK, Schenke WH, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001;142:248253.
  • 101
    Prasad K, Kalra J, Chan WP, Chaudhary AK. Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J 1989;117:11961202.
  • 102
    Prasad K, Kalra J, Chaudhary AK, Debnath D. Effect of polymorphonuclear leukocyte-derived oxygen free radicals and hypochlorous acid on cardiac function and some biochemical parameters. Am Heart J 1990;119:538550.
  • 103
    Prasad K, Kalra J, Lee P. Oxygen radicals as a mechanism of hypercholesterolemic atherosclerosis: Effects of probucol. Int J Angiol 1994;3:100112.
  • 104
    Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of Vitamin E. Am Heart J 1993;125:958973.
  • 105
    Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 2003;8:6169.
  • 106
    Prasad K. C-reactive protein and cardiovascular diseases. Int J Angiol 2003;12:112.
  • 107
    Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004;9:203209.
  • 108
    Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 2005;179:269275.
  • 109
    Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999;99:13551363.
  • 110
    Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172178.
  • 111
    Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363369.
  • 112
    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731733.
  • 113
    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:2028.
  • 114
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risks of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973979.
  • 115
    Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998:97:20072011.
  • 116
    Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:11911193.
  • 117
    Ridker PM, Rifai N, Pfeffer MA, Sacks F, Brawnwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230235.
  • 118
    Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:24812485.
  • 119
    Ridker PMJ, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836843.
  • 120
    Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794799.
  • 121
    Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:10181022.
  • 122
    Rouis M, Nigon F, Chapman MJ. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun 1988;156:12931301.
  • 123
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST Study. Clin Ther 2005;27:578587.
  • 124
    Sacks FM. High intensity statin treatment for coronary heart disease. JAMA 2004;291:11321134.
  • 125
    Schieffer B, Bunte C, Witte J, et al. C omparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362368.
  • 126
    Schram MT, Van Ittersum FJ, Spoelstra-de Man A, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in double-blind, randomized clinical trial. J Hum Hypertens 2005;19:429437.
  • 127
    Sebestjen M, Keber I, Zegura B, et al. Statin and fibrate treatment of combined hyperlipidemia: The effects on some novel risk factors. Thromb Haemost 2004;92:11291135.
  • 128
    Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 2003;38:813819.
  • 129
    Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004;27:468473.
  • 130
    Somogyi A, Herold M, Kocsis I, Nagy G, Somfai G, Studinger P. Effect of vitamin E supplementation on the vitamin content of lipoprotein in young men and woman. Orv Hetil 2005;146:18131818.
  • 131
    Steinberg D. Antioxidants in the prevention of human atherosclerosis. Circulation 1992;85:23372344.
  • 132
    Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:118119.
  • 133
    Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high sensitive C-reactive protein levels. Atherosclerosis 2003;169:155158.
  • 134
    Tan K, Chow W-S, Wong Y, Shiu S, Tam S. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria. Diabetes Care 2002;25:12541255.
  • 135
    Tan SA, Tan LG, Berk LS. Comparative study of the effects of rosiglitazone and pioglitazone on interferon-(gamma), tumor necrosis factor, interleukin-1(beta), interleukin-4, interleukin-6, and C-reactive protein in diabetic patients with atherosclerosis (Abstract). Diabetes 2002;51(Suppl 2):A595.
  • 136
    Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004;350:15621564.
  • 137
    Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coronary Artery Dis 2004;15:211217.
  • 138
    Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9:2733.
  • 139
    Undas A, Celinska-Lowenhoff M, Domagala TB, et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005;94:193199.
  • 140
    Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000;23:733738.
  • 141
    Van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-study Group Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003;166:129135.
  • 142
    Van den Akker JM, Bredie SJ, Diepenveen SH, Van Tits LJ, Stalenhoef AF, Van Leusen R. A torvastatin and simvastatin in patients on hemodialysis: Effect on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238244.
  • 143
    Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157163.
  • 144
    Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619625.
  • 145
    Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982;389:235250.
  • 146
    Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214218.
  • 147
    Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839846.
  • 148
    Wang CY, Chang TC. Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:47624767.
  • 149
    Wang L, Zhou YL, Lin SG. Association between angiotensin converting enzyme I/([A-Z]) polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril. Di Yi Jun Yi Da Xue Xue Bao 2005;25:691695.
  • 150
    Webster RO, Hong SR, Johnston RB Jr, Henson PM. Biological effects of the human complement fragments C5a and C5a des Arg on neutrophil function. Immunopharmacology 1980;2:201219.
  • 151
    Winegar DA, Brown PJ, Wilkison WO, et al. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001;42:15431551.
  • 152
    Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM; CADET Study, Investigators A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004;11:19341940.
  • 153
    Yamada S, Yanagawa T, Sasamoto K, Araki A, Miyao M, Yamanouchi T. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism 2006;55:6771.
  • 154
    Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:21162123.
  • 155
    Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004;116:460465.
  • 156
    Yesilbursa D, Serdar A, Saltan Y, et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol 2005;62:526530.
  • 157
    Yildiz MF, Kumru S, Godekmerdan A, Kutlu S. Effects of raloxifene, hormone therapy and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet 2005;90:128133.
  • 158
    Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting. The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:13751382.
  • 159
    Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:17971802.
  • 160
    Zegura B, Keber I, Sebestjen M, Koenig W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123129.
  • 161
    Zeller JM, Sullivan BL. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol 1992;52:449455.
  • 162
    Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macro-phages: Implications for atherosclerosis. Circulation 2001;103:11941197.
  • 163
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:14951504.